First Out Of The Gate, CSL Begins Adult Trials Of H1N1 Flu Vaccine

PERTH, Australia - Melbourne-headquartered CSL Limited will begin clinical trials of its H1N1 influenza vaccine in healthy adults ages 18 to 64 July 22, and pediatric trials will commence Aug. 1, CSL said